SBIO

Fund Description
The ALPS Medical Breakthroughs ETF invests in the public equity markets of the United States. It invests in the stocks of companies operating in the biotechnology and pharmaceutical sectors. The fund invests in stocks of mid cap and small cap companies with a market capitalization of no less than $200 million and no more than $5 billion. It seeks to replicate the performance of the Poliwogg Medical Breakthroughs Index, by investing in the stocks of companies as per their weightings in the index.
Fund Profile
Fund Name ALPS Medical Breakthroughs ETF
Fund Exchange Ticker SBIO
Fund Sponsor ALPS
Fund ISIN US00162Q5936
Net Expense Ratio 0.50 %
Fund Inception Date 31 December 2014
Fund Legal Structure ETF (Open end fund)
Exchange NYSE Arca
Listing Country Code US
Fund Investment Objective
ETF Type Specific US Equities - Industry Sector
Asset Class Equities (Stocks)
Index Linked Passive
Index Name Poliwogg Medical Breakthroughs Index
Index Provider Poliwogg Index
Currency Hedged No
Inverse / Leveraged Not Applicable
Developed / Emerging Developed Market Funds
Market Capitalization Range SMID (Small & Mid) Cap
Growth Value Core / Blend
Continent North America
Key Statistics
Return As of Date 19 June 2019
Asset Under Management 190.80 Million (USD)
1 Month Total Return 9.46 %
Year To Date Return 27.86 %
1 Year Total Return -3.73 %
3 Year Annualized Total Return 16.55 %
NAV 36
Share Outstanding 5,300,000
Top 10 Holdings (19 June 2019)
Constituent Name Constituent Ticker Constituent Type Weighting
ARRAY BIOPHARMA INC ARRY EQUI 0.0898000000
GALAPAGOS NV GLPGF EQUI 0.0554000000
ASCENDIS PHARMA A/S - ADR ASND EQUI 0.0448000000
MIRATI THERAPEUTICS INC MRTX EQUI 0.0421000000
GLOBAL BLOOD THERAPEUTICS IN GBT EQUI 0.0396000000
ARENA PHARMACEUTICALS INC ARNA EQUI 0.0349000000
UNIQURE NV QURE EQUI 0.0349000000
AGIOS PHARMACEUTICALS INC AGIO EQUI 0.0349000000
FIBROGEN INC FGEN EQUI 0.0346000000
IMMUNOMEDICS INC IMMU EQUI 0.0307000000